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Abstract
Network meta-analysis (NMA) is a statistical technique for the comparison of treat-
ment options. The nodes of the network are the competing treatments and edges
represent comparisons of treatments in trials. Outcomes of Bayesian NMA include
estimates of treatment effects, and the probabilities that each treatment is ranked best,
second best and so on. How exactly network geometry affects the accuracy and preci-
sion of these outcomes is not fully understood. Here we carry out a simulation study
and find that disparity in the number of trials involving different treatments leads
to a systematic bias in estimated rank probabilities. This bias is associated with an
increased variation in the precision of treatment effect estimates. Using ideas from
the theory of complex networks, we define ameasure of ‘degree irregularity’ to quan-
tify asymmetry in the number of studies involving each treatment. Our simulations
indicate that more regular networks have more precise treatment effect estimates
and smaller bias of rank probabilities. We also find that degree regularity is a bet-
ter indicator of NMA quality than both the total number of studies in a network and
the disparity in the number of trials per comparison. These results have implica-
tions for planning future trials. We demonstrate that choosing trials which reduce the
network’s irregularity can improve the precision and accuracy of NMA outcomes.
KEYWORDS:
network meta-analysis, simulation study, rank probability, network geometry and degree irregularity,
planning future trials
1 INTRODUCTION
Meta-analysis is an important statistical technique used to
combine the results of multiple randomised controlled trials.
Often, individual trials have small sample sizes and involve
subjects taken from a reduced population. Because of this, it is
desirable to systematically integrate results from different tri-
als that address the same clinical question. Over the last four
decades meta-analysis has therefore become invaluable for the
comparison of treatment options1.
Conventional meta-analysis focuses on pairwise compar-
isons of treatments. More recently however, network meta-
analysis (NMA) has emerged as a technique for making infer-
ences about multiple competing treatments. NMA allows one
to combine data from multiple trials even when different tri-
als test different sets of treatment options. The term ‘network
meta-analysis’ derives from a graphical representation of the
treatments and trials. The nodes of the network graph are the
different treatment options and the connecting edges represent
comparisons made between the treatments in the trials. NMA
combines both direct and indirect evidence for the assessment
of treatments. This makes it possible to compare treatments
that have not been tested together in any trial2,3,4,1.
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2 DAVIES and GALLA
Bayesian NMA in particular has undergone substantial
development over recent years. At the same time, it is also
recognised that further research is required to fully under-
stand its limitations and to improve the method5,6. In this
context, simulation studies are frequently used to evaluate the
performance of NMA and the factors affecting its accuracy7.
This approach involves setting up a model (e.g. a fixed-effect
or random-effect model8,2) with parameters whose numerical
values can be fixed at the beginning. The model is used to pro-
duce synthetic (computer-generated) trial data9. Estimates of
the model parameters are then obtained by feeding this syn-
thetic data into the NMA method. The outcome of the NMA
can then be compared against the known model parameters.
A key strength of this approach is the ability to systemati-
cally vary the parameters of the model. For example, different
relative treatment effects can be explored, or the structure of
the network of treatments and trials can be changed. This
allows one to systematically investigate the performance of
NMA in a range of different scenarios, and to determine the
nature of any inaccuracies or biases. To do this, however,
Bayesian NMAs must be carried out for many realisations of
the synthetic trial data. The overall computational effort can
be considerable because the NMA method relies on extensive
Markov Chain Monte Carlo sampling10,11.
The primary outcomes of an NMA are estimates of rela-
tive treatment effects, and the corresponding credible intervals.
Bayesian NMA allows one to rank treatments based on these
relative effects, providing a convenient summary for clinical
decision making. However, simply ranking treatments as best,
second best and so on can be misleading as it does not take into
account the level of overlap between credible intervals12.
As a consequence, a number of other metrics have been
developed to compare treatments. One such metric focuses
on so-called ‘rank probabilities’. These quantify the degree
of certainty with which each treatment is believed to be the
most effective, second most effective, etc., based on the avail-
able trial data. Results are often reported in terms of so-called
SUCRAvalues (‘surface under the cumulative ranking curve’).
These values condense rank probabilities into a numerical
summary13, and reflect both the magnitude and the uncertainty
of treatment effect estimates6,14,15.
Ranking methods have attracted considerable interest in
recent years14,16,17,18,19,20. It is generally recognised that the
accuracy of ranking statistics and the treatment effect estimates
are likely to be affected by the geometry of the network of treat-
ments and trials21,22,17,23,5. PRISMA guidelines (‘Preferred
Reporting Items for Systematic Reviews and Meta-Analyses’)
therefore recommend that authors provide graphical and qual-
itative descriptions of network geometry6.
A previous simulation study found that the probability of
being ranked first is overestimated for the treatment that is
tested in the fewest studies in a given network, and underesti-
mated for the treatment included in the most studies24. It has
been suggested that this is due to differences in the precision
of treatment effect estimates15. Overall it is generally accepted
that reporting only the probability of being best can lead to
erroneous conclusions17,25,14. Indeed, the current advice from
the PRISMA guidelines is to report the probability that each
treatment has each rank6.
In practice however, the most common ranking statistic in
NMAs continues to be the probability that each treatment is
ranked best26. Previous research on the utility of rank proba-
bilities has also focused almost exclusively on the probability
of being ranked best. As a result there is very limited evidence
on the validity of reporting the full set of rank probabilities
or the SUCRA values. Furthermore, due to a lack of appro-
priate data-generating models and the high computing power
required to carry out Bayesian NMAs, simulation studies have
been limited to fixed-effects models or networks of two-arm
trials only24,27. Some progress been made in relating charac-
teristics of network geometry to the outcome of NMA22,21,28.
However, it is largely unexplored how exactly these metrics
relate to the performance of ranking statistics and treatment
effect estimates5.
The purpose of our work is to study how the structure of the
network affects the probability that each treatment is ranked
first, second and so on. In particular we go beyond the proba-
bility of being ranked best.We also investigate themechanisms
by which the network affects rank probabilities. Building on
recent advances in data-generating methods29, our simula-
tion studies include random-effects models and networks of
multi-arm trials. In order to characterise network geometry we
introduce a measure of asymmetry in the number of studies
per treatment which we call ‘degree irregularity’. The network
is said to be regular if all treatments are tested in the same
number of studies, and it becomes increasingly more irregular
the more this number varies across treatments. Through sim-
ulations of multiple network geometries we investigate how
this metric affects the precision and accuracy of the treatment
effect estimates, and the quality of rank probability estimates
and SUCRA values. These results provide a simple method for
the identification of additional trials which best complement
an existing network of evidence.
The remainder of this paper is set out as follows: In Section
2 we present the relevant background information and meth-
ods. We begin by outlining the random-effects model for a
network of multi-arm trials and the Bayesian approach to
NMA. Following this we define the key outcomes of NMA
and the relevant ranking statistics. The design of the simu-
lation and networks are described along with details of the
data-generating models. We also introduce treatment-specific
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and network-level quantities that allow us to compare the qual-
ity of NMA outcomes within and between networks. Section
3 contains our main results. First, we present within-network
and between-network comparisons for networks with equally
effective treatments and two-arm trials. We then test how well
these results generalise to scenarios in which the true treatment
effects vary across treatments, and we study networks involv-
ing multi-arm trials. We also compare the results from three
different data-generating models. In Section 4 we summarise
and discuss our main findings. We provide an example that
demonstrates how our results can be used to inform the choice
of future trials.
2 METHODS
2.1 General setup: network of trials
We consider a collection of 푁 treatments, which we label
훼 = 푇1, 푇2,… , 푇푁 . The network contains 푀 trials, denoted
푖 = 1,… ,푀 . Each trial compares a subset of treatments,
퐴푖 ⊂ {푇1,… , 푇푁}; 푚푖 = |퐴푖| is the number of treatments in
trial 푖. We use the notation 푡푖,퓁 to label the treatments compared
in trial 푖, where 퓁 = 1,… , 푚푖. Each 푡푖,퓁 is therefore a treatment
from the set {푇1,… , 푇푁}.
As an example, consider a network of smoking cessation
data reported by Hasselblad30. Four treatments are compared:
푇1 = no contact (control), 푇2 = self-help, 푇3 = individual
counselling and 푇4 = group counselling. The network is shown
in Figure 1 and consists of 24 trials. Trial 푖 = 2 in Hasselblad30
compares 푚2 = 3 treatments such that 푡2,1 = 푇1 (no contact),
푡2,2 = 푇3 (individual counselling) and 푡2,3 = 푇4 (group coun-
selling). Trial 푖 = 6, on the other hand, compares 푚6 = 2
treatments; 푡6,1 = 푇2 (self-help) and 푡6,2 = 푇3 (individual
counselling). In Figure 1(a), these two trials are highlighted by
dashed and dotted lines respectively. Showing all 24 individual
trials in this way would result in a rather cumbersome graph.
It is therefore common not to indicate trials individually in
the network. Instead, two treatments are connected by an edge
whenever there is at least one trial involving both treatments.
In the example, this means that edges are present between all
pairs of treatments. For each pair, the thickness of the link is
proportional to the number of trials comparing these two treat-
ments. This turns the graph into a ‘weighted network’31. In our
illustrations, the diameter of each node is proportional to the
number of participants that have received the treatment rep-
resented by the node. For the network in Hasselblad30, this
results in Figure 1(b).
The treatments in trial 푖 are referred to as the arms of the
trial. For a given trial 푖, the treatment in arm 퓁 is administered
to 푛푖,퓁 patients. We assume a binary outcome, i.e. the applica-
tion of the treatment to a particular patient either produces an
FIGURE 1 Graphical representation of the network of treat-
ments and trials for smoking cessation30.The four treatments
are: 푇1 = no contact (control), 푇2 = self-help, 푇3 = individ-
ual counselling and 푇4 = group counselling. In panel (a), trials
푖 = 2 (a 3-arm study) and 푖 = 6 (a 2-arm study) are high-
lighted by dashed and dotted lines respectively. The thickness
of each egde in panel (b) is proportional to the number of stud-
ies that make that comparison, and the diameter each node is
proportional to the number of participants who received that
treatment.
‘event’, or it does not. The number of resulting events, 푟푖,퓁 , is
then recorded for each trial and arm. This means that trial 푖 is
defined by the treatments it compares, 퐴푖 = 푡푖,1,… , 푡푖,푚푖 , andby the number of patients in each arm, 푛푖,퓁 . The trial reports
dichotomous data of the form (푟푖,1, ..., , 푟푖,푚푖).The model assumes that the application of the treatment in
arm 퓁 of trial 푖 generates events with probability 푝푖,퓁 indepen-
dently for each of the 푛푖,퓁 patients at the end of this trial arm32.
As a consequence of this setup, each 푟푖,퓁 is a binomial random
variable,
푟푖,퓁 ∼ Bin(푛푖,퓁 , 푝푖,퓁), (1)
for 푖 = 1,… ,푀 and 퓁 = 1,…푚푖.
We use a random-effects model, i.e. 푝푖,퓁 may be different
from 푝푖′,퓁′ in different trials (푖 ≠ 푖′), even if 푡푖,퓁 = 푡푖′,퓁′ .
That is to say, the effectiveness of any fixed treatment 훼 ∈
{푇1,… , 푇푁} may be different in different trials.
Following the generalised linear model framework, the
probabilities 푝푖,퓁 are described on the logit scale33. We use the
notation logit(푝) = ln 푝 − ln(1 − 푝) for 0 < 푝 < 1.
Our analysis focuses on relative rather than absolute treat-
ment effects. To this end, we refer to treatment 푡푖,퓁=1 as the
‘baseline’ treatment of trial 푖. We write 푏푖 = logit 푝푖,1 for
the absolute treatment effect of this trial-specific baseline. For
퓁 ≠ 1 we then define the relative treatment effect 훿푖(퓁),
훿푖(퓁) ≡ logit(푝푖,퓁) − 푏푖. (2)
The trial-specific baseline treatment effect, 푏푖, is the log odds of
the outcome in arm 퓁 = 1 of trial 푖, while the relative treatment
effect is the log odds ratio of treatment 퓁 ≠ 1 compared to the
trial-specific baseline.
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2.2 Random-effects model
A contrast-based approach to the random-effects model
assumes the exchangeability of relative, rather than absolute
treatment effects34,35,36. This indicates that the relative effect
of two treatments 훼 and 훽 is drawn from the same distribution
for any trial involving these two treatments, no matter what
value the index 푖 takes for this trial. The function of the index 푖
is therefore purely to distinguish trials, it does not contain any
other a-priori information about the effectiveness of treatments
in that trial.
We assume that the relative treatment effects for a given trial
푖 are drawn from a multivariate normal distribution
⎛⎜⎜⎝
훿푖(2)
⋮
훿푖(푚푖)
⎞⎟⎟⎠ ∼
⎛⎜⎜⎜⎝
⎛⎜⎜⎜⎝
푑푡푖,1푡푖,2
⋮
푑푡푖,1푡푖,푚푖
⎞⎟⎟⎟⎠ ,횺풊
⎞⎟⎟⎟⎠ . (3)
This means that the relative effect 훿푖(퓁) of the 퓁-th treatment
in trial 푖 (compared to the baseline treatment of trial 푖) is drawn
from aGaussian distributionwithmean 푑푡푖,1,푡푖,퓁 . The latter quan-tity is the mean effect of treatment 푡푖,퓁 relative to the baseline
treatment 푡푖,1 of trial 푖. That is to say, it is the average relative
treatment effect one would see in a large sample of trials com-
paring these two treatments. We assume that these unknown
mean relative treatment effects fulfill the consistency relations
푑훼훽 = 푑훼훾 − 푑훽훾 . (4)
The (푚푖 − 1) × (푚푖 − 1) covariance matrix 횺풊 in Equation (3)
describes the between-trial variance of the relative treatment
effects, and their correlations. Following References37,38,4, we
will assume that its diagonal elements are all identical. We
write 휏2 for their common value. This is the variance of each
훿푖(퓁). We will further assume that the covariance between any
two treatment effects is 휏2∕2 (these are the off-diagonal ele-
ments of 횺풊). This ensures that the relative effect 훿푖(퓁)−훿푖(퓁′)
between any two treatments 퓁 ≠ 퓁′ in trial 푖 has variance 휏2.
The aim of network meta-analysis is to estimate the mean
treatment effects 푑훼훽 for all pairs 훼 ≠ 훽, and the heterogeneity
parameter, 휏. Given the consistency assumption (4), not all 푑훼훽
are independent. As a consequence, we can use treatment 훼 =
푇1 as the overall global baseline treatment, and it is sufficient
to estimate 푑푇1훼 for 훼 = 푇2,… , 푇푁 39.
2.3 Bayesian network meta-analysis
We write 풅 = (푑푇1푇2 , 푑푇1푇3 ,… , 푑푇1푇푁 ) for the vector of meantreatment effects relative to the global baseline. The vector 풏
contains the numbers of patients in all arms in the network
and 풓 contains the trial outcomes. Bayesian NMA aims to con-
struct posterior distributions for the model parameters, (풅, 휏),
conditional on the data, (풓,풏). This is achieved using appro-
priate likelihood functions and prior distributions40,4. We use
non-informative prior distributions for the model parameters.
Specifically, we assume independent univariate Gaussian dis-
tributions (0, 104) for each of the parameters 푏푖 and 푑훼훽 . The
prior for 휏 is assumed to be a uniform distribution over the
interval from 0 to 52,41. As described by Smith et al (1995),
the joint likelihood function of all the model parameters,
({훿푖(퓁)}, {푏푖},풅, 휏), can be constructed from the product of so-
called conditional ‘parent-child’ probability distributions40. In
the case of the random-effects model for dichotomous data we
have described, Eqs. (1) to (3) are used to construct a likeli-
hood which is a product of binomial and multi-variate normal
distributions.
For this setup, the posterior distributions of the model
parameters can usually not be obtained analytically. We there-
fore rely on MCMC methods, specifically the Metropolis-in-
Gibbs algorithm42,10,43,11. MCMC approaches work by con-
structing a Markov chain whose stationary distribution is the
probability distribution of interest. In Bayesian NMA this is
the posterior distribution of themodel parameters, (풅, 휏), given
the data.
Following Kibret et al (2014)24, we used a burn-in of 5×103
and a thinning factor of 10 in our MCMC simulations. Sam-
ples were drawn from the posterior distributions for 2 × 104
iterations after burn-in.
2.4 Reporting NMA outcomes
The primary outcomes from an NMA are the final estimates of
the model parameters and their uncertainty (the latter is usu-
ally indicated by a 95% credible interval). In addition, Bayesian
NMA allows for the calculation of rank probabilities {푃훼(푟)}.
The quantity 푃훼(푟) is the probability that treatment 훼 is ranked
푟-th. At each MCMC iteration the treatments are ranked from
best (rank 푟 = 1) to worst (rank 푟 = 푁) based on the values of
푑푇1훼 sampled at that iteration. After discarding the burn-in, andcarrying out thinning as described, the rank probabilities are
estimated from the proportion of times each treatment received
each rank.
Treatment effect estimates and ranking probabilities become
more difficult to interpret as the number of treatments in
the network increases17,14. In order to simplify this informa-
tion, Salanti et al (2011) introduced a numerical summary,
the so-called ‘surface under the cumulative ranking’ curve
(SUCRA)13. The value of SUCRA for treatment 훼 is defined
as
SUCRA훼 = 1푁 − 1
푁−1∑
푟=1
퐹훼(푟), (5)
where 퐹훼(푟) is the probability that treatment 훼 has rank 푟 or
better13,15,
퐹훼(푟) =
푟∑
푠=1
푃훼(푠). (6)
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Using the definition of the expected rank,
⟨푟⟩훼 = 푁∑
푟=1
푟푃훼(푟), (7)
it is straightforward to see that15
SUCRA훼 = 1푁 − 1(푁 − ⟨푟⟩훼). (8)
In this notation SUCRA takes values between zero and one. In
practice, SUCRA values are often expressed as a percentage:
if a treatment is ranked first with probability one then it will
have SUCRA = 1 (or 100%), and if it ranks last with certainty,
then it will have a SUCRA = 0 (or 0%)13.
2.5 Network design
Simulations in our work were restricted to networks with푁 =
4 treatments. Figure 2 shows the five network geometries we
have used: (a) star, (b) loop, (c) complete loop, (d) tadpole,
and (e) ladder. These geometries were chosen as they are
commonly observed in real-life network meta-analyses; com-
binations of these have been previously studied in27,24,39,22.
Within the constraints of these geometries, the num-
ber of studies per comparison was varied (i.e., the num-
ber of trials involving a particular pair of treatments). To
describe the specific geometry of a network we use the
vector of the number of studies per comparison, 푲 =
(퐾푇1푇2 , 퐾푇1푇3 , 퐾푇1푇4 , 퐾푇2푇3 , 퐾푇2푇4 , 퐾푇3푇4), where 퐾훼훽 = 퐾훽훼 isthe number of studies that compare treatments 훼 and 훽. The
entries of 푲 define the strengths (or weights) of the edges in
the network of treatments.
We note, however, that the full setup of the treatment–trial
network is not fully specified by 푲 alone. This is because the
same number of comparisons per pair of treatments can be
achieved by different combinations of two-arm and multi-arm
trials.
From 푲 we can obtain the number of studies involving
treatment 훼,
푘훼 =
∑
훽≠훼
퐾훼훽 . (9)
In the theory of networks this quantity is referred to as the
‘weighted degree’ of node 훼 31. We will occasionally use
slightly more casual language, and refer to 푘훼 as the ‘number
of studies per treatment’. We also define the average number
of studies that a treatment is involved in (the ‘mean degree’),
푘̂ = 1
푁
∑
훼
푘훼 . (10)
In network theory, a graph is said to be ‘regular’ if all nodes
have the same degree31. With this in mind, we introduce a
measure of ‘degree irregularity’ of the network,
ℎ2 = 1
푁
∑
훼
(푘훼 − 푘̂)2. (11)
FIGURE 2 Network diagrams of the five network geometries
considered in this study: (a) star (b) loop (c) complete loop (d)
tadpole (e) ladder.
This quantifies the variation in the number of studies per treat-
ment. In particular, ℎ2 = 0 when all nodes are involved in
the same number of trials (푘훼 = 푘̂ for all 훼). When we make
comparisons between networks we use the normalised network
irregularity, ℎ2∕푘̂2.
We note that there is a direct mapping between ℎ2∕푘̂2 and
the so-called ‘probability of inter-specific encounter index’
(PIE). This index is a measure of ecological diversity, and
was introduced to network meta-analysis by Salanti et al
(2008)21,22. Further details can be found in Section S1 in the
Supplementary Material44.
Some of the key quantities we use in our analysis are
summarised in Table 1.
2.6 Simulation method
In our simulations we generate dichotomous trial data for a
specified network geometry and for known model parame-
ters (풅, 휏). An NMA is performed for multiple independent
realisations of simulated data, and the resulting estimates of
the model parameters are recorded for each realisation. More
specifically, we used the following numerical protocol:
(1) Define the fixed parameters of the network such as the total
number of studies,푀 , the vector of number of studies per
comparison, 푲 , the number of participants in each arm,
푛푖,퓁 , and the true model parameter values (풅, 휏).
(2) Generate and analyse independent realisations 휈 =
1, 2, ...,Ω of synthetic trial outcomes. Specifically, for each
휈:
(a) For all trials 푖, randomly sample the {훿푖(퓁)}, 퓁 =
2,… , 푚푖, from the multivariate normal distribution in
Equation (3).
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TABLE 1 Summary of key quantities used in our analysis.
Variable Definition
푁 Total number of treatments in the network
푀 Total number of studies in the network
푑훼훽 True mean relative treatment effect between
treatments 훼 and 훽
휏 Heterogeneity parameter
푘훼 Number of studies involving treatment 훼
푘̂ Mean degree of the network (mean number
of studies a treatment is involved in)
ℎ2∕푘̂2 Normalised degree irregularity
SD(푑)훼 Treatment-specific standard deviation of the
treatment effect estimate⟨Δ푃훼(푟)⟩ Bias of the rank probability estimate, aver-
aged over realisations of synthetic trial data
SD Total standard deviation of treatment effect
estimates in the network|Δ푃 | Total rank probability bias in the network|ΔSUCRA| Total SUCRA bias in the network
(b) Using the {훿푖(퓁)} and one of the three data-generating
models (see Section 2.7), construct the probabilities
푝푖,퓁 , 퓁 = 1,… , 푚푖, for all trials 푖 in the network.
(c) For each trial arm, generate random event data, 푟푖,퓁 ,
from the binomial distribution in Equation (1).
(d) Use the vector of events, 풓, and vector of participants,
풏, to carry out a Bayesian NMA.
(e) Determine the treatment effects with respect to the
baseline 푇1 and use the consistency relation in
Equation (4) to output the estimated model parame-
ters, 푑̃(휈)훼훽 , for all 훼, 훽 ∈ {푇1,… , 푇푁}. Also output theestimated heterogeneity parameter, 휏̃ (휈), and the bias
of rank probabilities,
Δ푃 (휈)훼 (푟) = 푃̃
(휈)
훼 (푟) − 푃훼(푟). (12)
In this equation 푃̃ (휈)훼 (푟) is the probability that treatment
훼 has rank 푟 in the NMA of realisation 휈.
(3) Calculate the mean and standard deviations of the esti-
mated model parameters over realisations, for example
⟨푑̃훼훽⟩ = 1Ω Ω∑휈=1 푑̃(휈)훼훽 , (13)
SD(푑̃훼훽) =
√√√√ 1
Ω − 1
Ω∑
휈=1
(푑̃(휈)훼훽 − ⟨푑̃훼훽⟩)2, (14)
with similar definitions for ⟨휏̃⟩, SD(휏̃), ⟨Δ푃훼(푟)⟩ and
SD(Δ푃훼(푟)).
2.7 Data generation for simulation studies
The relative treatment effects 훿푖(퓁) (퓁 = 2,… , 푚푖) in any one
trial 푖 do not uniquely define the absolute treatment effects 푝푖,퓁 .
This is because the treatment effect of the trial-specific base-
line, 푝푖,1, is not determined by the {훿푖(퓁)}. Equation (2) can be
re-arranged to give
푝푖,퓁 = 푝푖,퓁[푝푖,1, 훿푖(퓁)] =
푝푖,1 exp(훿푖(퓁))
1 − 푝푖,1
(
exp(훿푖(퓁)) − 1
) , (15)
so that 푝푖,1 together with the {훿푖(퓁)} (퓁 = 2,… , 푚푖) specifies
all absolute treatment effects in trial 푖.
To fully define step (2)(b) in the above algorithm it is there-
fore sufficient to specify the construction of 푝푖,1. In the context
of the random-effects model and to allow for the inclusion of
multi-arm trials, we use three data-generating models (DGM)
based on those presented by Seide et al (2019)29.
The first DGM, which we will call ‘Euclidean’, chooses the
treatment effect for the baseline treatment to be the value that
minimises the Euclidean distance of the vector (푝푖,1,… , 푝푖,푚푖)from the vector (1∕2,… , 1∕2), i.e.,
푝푖,1 = min푞
[(
푞 − 1
2
)2
+
푚푖∑
퓁=2
(
푝푖,퓁
[
푞, 훿푖(퓁)
]
− 1
2
)2]
, (16)
where 푝푖,퓁[⋅, ⋅] is the expression given in Equation (15). This is
referred to as ‘DGM “Fixed”Modified’ in Seide et al (2019)29.
The other two methods are variations of the DGM “Fixed" in
Seide et al (2019)29 which we will refer to as ‘Uniform’ and
‘Normal’ respectively. The former samples 푝푖,1 from a uniform
distribution between zero and one, whilst the latter samples it
from a normal distribution (0.5, 0.2), truncated at zero at the
lower end, and at one at the upper end. To ensure our results
were not due to the data-generatingmodel, all simulationswere
performed using each method and the results compared.
2.8 Quantities indicating and characterising
NMA quality
In this section we introduce quantities that measure the quality
of the parameter estimates resulting from the NMA. We begin
with treatment specific values. These are used to compare how
well an NMA estimates the effectiveness of each treatment
within a given network.
For each pair of treatments 훼 ≠ 훽 we define the mean bias
of the relative treatment effect,
⟨Δ푑훼훽⟩ = ⟨푑̃훼훽⟩ − 푑훼훽 . (17)
For each fixed treatment 훼 we can also define the treatment-
specific mean bias
⟨Δ푑⟩훼 = 1푁 − 1∑훽≠훼⟨Δ푑훼훽⟩. (18)
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Similarly, the treatment-specific standard deviation of the
treatment effect is defined as
SD(푑)훼 = 1푁 − 1
∑
훽≠훼
SD(푑̃훼훽). (19)
Bias of SUCRA훼 values and bias of probability ranks,⟨Δ푃훼(푟)⟩, are treatment specific quantities by construction.
The former can be written in terms of the latter,
⟨ΔSUCRA훼⟩ = −∑푟 푟⟨Δ푃훼(푟)⟩푁 − 1 . (20)
Next we define network-level indicators allowing compar-
isons of the quality of NMA outcomes between networks. We
introduce the total magnitude of the bias of rank probability,
|Δ푃 | =∑
훼
∑
푟
|⟨Δ푃훼푟⟩|, (21)
and the total magnitude of the bias of SUCRA,
|ΔSUCRA| =∑
훼
|⟨ΔSUCRA훼⟩|. (22)
To be able to compare numerical values for these two quanti-
ties with each other, we express these indicators as proportions
of the maximum values they can take, see Section S2 in the
Supplementary Material44 for further details.
Finally, we introduce the total standard deviation and total
bias of treatment effects,
SD =∑
훼
SD(푑)훼 , (23)
|Δ푑| =∑
훼
|⟨Δ푑⟩훼|. (24)
Refer to Table 1 for a summary of some of these quantities.
3 RESULTS
The set of simulated networks was chosen to cover a range of
values for the degree irregularity ℎ2∕푘̂2. It includes all net-
work geometries in Figure 2, with varying values of 푲 =
(퐾푇1푇2 , 퐾푇1푇3 , 퐾푇1푇4 , 퐾푇2푇3 , 퐾푇2푇4 , 퐾푇3푇4). We used 휏 = 0.1throughout, as well as an equal number of participants per arm,
푛푖,퓁 = 25, and Ω = 103 independent realisations of synthetic
trial outcomes for any fixed set of model parameters (풅, 휏).
Error bars in our figures are typically smaller than the size of
the markers.
In Sections 3.1 and 3.2 we first focus on networks with
equally effective treatments, 풅 = (푑푇1푇2 , 푑푇1푇3 , 푑푇1푇4) =
(0, 0, 0). Any systematic effect observed in the outcome of
NMA is therefore a result of the structure of the network
only. Networks with treatments of varying effectiveness are
discussed in Section 3.3.
FIGURE 3 The effect of the number of studies per treatment
on the bias on rank probabilities, Δ푃훼(푟), for 푟 = 1, 2, 3, 4.
These plots are for a star network with 푲 = (1, 5, 15, 0, 0, 0).
3.1 Comparisons within networks
In Figure 3 we plot bias of rank probability against number
of studies per treatment, 푘훼 , for a star network with 푲 =
(1, 5, 15, 0, 0, 0). Similar plots for other network geometries
can be found in the Supplementary Material44 (Figures S1 to
S16). This data consistently shows that the probability to be
ranked best or worst, 푃훼(1) and 푃훼(4) respectively, is overesti-
mated for the treatment included in the fewest studies (lowest
degree 푘훼). The probabilities 푃훼(2) and 푃훼(3) are underesti-
mated. The reverse is found for the treatment included in the
most studies.
The bias of rank probability for the treatments with the
most and fewest studies appears to be common in all networks.
We find that the bias of the remaining two treatments can be
affected by the position of their respective nodes in the net-
work. Figure 4 shows the bias of 푃훼(1) for a ladder network
with 푲 = (1, 0, 0, 5, 0, 15). In this example treatment 푇2 is
included in fewer studies (푘푇2 = 6) than treatment 푇4 (푘푇4 =
15) but has more direct comparisons (it is directly compared
to 푇1 and 푇3 whereas treatment 푇4 is only directly compared
to 푇3). The bias on 푃훼(1) for treatment 훼 = 푇2 is found to be
more negative than that of treatment 훼 = 푇4.
We conclude that disparity in the number of studies per treat-
ment generates a trend in bias of rank probabilities. It is natural
to ask if a similar trend is found for bias of treatment effect esti-
mates. This appears not to be the case (see Figures S1 to S16
in the Supplementary Material44).
Instead, the trend in Δ푃훼(푟) is associated with a systematic
pattern in the standard deviation of treatment effect estimates,
see Figure 5. We find that SD(푑)훼 tends to decrease with
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FIGURE 4 Ladder network with 푲 = (1, 0, 0, 5, 0, 15). An
example demonstrating the effect of node position on rank
probability bias.
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FIGURE 5 Standard deviation of treatment effect estimates.
On the horizontal axis, we use the normalised number of stud-
ies, 푘훼∕푀 , to capture how well connected a treatment is in the
network. Each network contributes four data points, one for
each treatment. The figure includes the data from all irregular
networks we simulated.
the number of studies treatment 훼 is involved in. The stan-
dard deviation, SD(푑)훼 , is particularly high for treatments with
푘훼∕푀 ≲ 0.1 and appears to flatten out for those included in
a larger proportion of studies. We note, however, that Figure 5
includes data from multiple networks. On inspection of indi-
vidual networks, we find a slight but consistent decrease in
SD(푑)훼 as the number of studies of treatment 훼 increases (see
Figures S1 to S16 in the Supplementary Material44). This
data suggests that bias in the rank probabilities may originate
from a variation in the uncertainties of the different treatment
effect estimates. A possible mechanism for this is discussed in
Section 4.
3.2 Comparisons between networks
So far we have mostly compared the outcome of NMA for
different treatments within a given network. In this section
we make comparisons between different networks. One main
observation is a positive association between the degree irreg-
ularity of a network, ℎ2∕푘̂2, and the total bias on rank prob-
abilities, |Δ푃 |. The data shown as red circles in Figure 6
demonstrate this for networks with equally effective treat-
ments.
While we find no relationship between irregularity and total
bias of relative treatment effects, |Δ푑|, (see Figure S21 in the
Supplementary Material44) Figure 7 shows that the total stan-
dard deviation of the estimates of relative treatment effects,
SD, increases with ℎ2∕푘̂2. Therefore networks with a more
homogeneous distribution of studies lead not only to lower bias
of rank probabilities, but also to more precise estimates of rel-
ative treatment effects. This is also a possible explanation for
the vertical spread in Figure 5. Different data points for a given
value of 푘훼∕푀 can be from networks with varying degrees
of irregularity and hence they result in different outcomes for
SD(푑)훼
We find that the total bias in rank probability estimates,
Δ푃 , and the total standard deviation of treatment effect esti-
mates, SD, are not systematically affected by the total number
of studies in the network (Figures S22 and S23 in the Supple-
mentary Material44). This has implications for the planning of
future studies to be added to an existing network. Naively, one
may assume that adding any study to an existing network will
improve the quality of results because the amount of evidence
is increased. However our results suggest that, in terms of bias
on rank probabilities and the precision of treatment effect esti-
mates, this is only true if the addition of the study reduces the
degree irregularity, ℎ2∕푘̂2, of the network.
The data shown as red circles in Figure 8 demonstrate that,
for networks with equally effective treatments, network irreg-
ularity has no effect on the total bias of SUCRA values across
the network. Comparing the data in Figures 6 and 8 we find
that the bias of SUCRA is approximately ten times smaller
than that of the rank probabilities. This is consistent with the
data in Figure 3 which shows that the biases of 푃훼(2) and 푃훼(3)
are almost the exact negative of the biases of 푃훼(1) and 푃훼(4).
These biases cancel in calculation of SUCRA in Equation (5).
The same reasoning also explains why, when making within-
network comparisons, the number of studies per treatment
has no effect on the bias of SUCRA훼 (see Figure S17 in the
Supplementary Material44).
3.3 Treatments of varying effectiveness
The data presented so far is for networks with equally effec-
tive treatments, 풅 = (0, 0, 0). In order to test the robustness
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FIGURE 6 The effect of degree irregularity on a network’s
total rank probability bias for networks with equally effective
treatments and non-equally effective treatments.
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FIGURE 7 The effect of degree irregularity on a network’s
total standard deviation, SD, for networks with equally effec-
tive treatments and non-equally effective treatments.
of our findings, we now focus on a case in which the four
treatments have different effectiveness. Specifically, we choose
풅 = (0.5, 1.0, 1.4), and study the same network geometries as
before. Treatment 푇1 is now the most effective, followed by
푇2, then 푇3 and treatment 푇4 is the least effective. Therefore
the ‘true’ rank probabilities are 푃푇1(1) = 푃푇2(2) = 푃푇3(3) =
푃푇4(4) = 1.0 and all other 푃훼(푟) are zero.
As shown in Figure 7, the relationship between SD and
degree irregularity is the same as in the case of equally effec-
tive treatments (풅 = (0, 0, 0)); the numerical values of SD are
also found to be largely similar, there is no systematic increase
or reduction in the standard deviation.
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FIGURE 8 The effect of degree irregularity on a network’s
total SUCRA bias for networks with equally effective treat-
ments and non-equally effective treatments.
The qualitative effect of degree irregularity, ℎ2∕푘̂2, on the
total magnitude of the bias of rank probabilities, |Δ푃 |, is simi-
lar compared to the case of equally effective treatments (Figure
6). For ℎ2∕푘̂2 ≳ 0.2 we find that the bias is larger for treat-
ments with varying effectiveness than for equally effective
treatments.
In our analysis of the case 풅 = (0.5, 1.0, 1.4)we find that the
standard deviations, SD(푑훼훽), range from approximately 0.1 to
1.0. This means that there is significant overlap in the distri-
butions of the estimated treatment effects. As a consequence
of this, the treatments appear to be similarly effective on aver-
age. For treatments with varying effectiveness, the true rank
probabilities take values of either 0 or 1, whereas for networks
with equally effective treatments, all 푃훼(푟) are equal to 0.25. It
is therefore natural that the bias of rank probabilities is greater
for networks of treatments with different effectiveness, at least
when the magnitude of SD(푑훼훽) is of the same order or larger
than the disparity in true treatment effects.
Figure 8 shows that, in contrast to the results for networks
with equally effective treatments, |ΔSUCRA| increases with
ℎ2∕푘̂2 for 풅 = (0.5, 1.0, 1.4). On inspection of the biases
of rank probabilities within a given network (Figure S20 in
the Supplement44) we find that the relationship between rank
probability bias and the number of studies per treatment is
affected by the quality of the treatments that have been com-
pared. Unlike in Figure 3 (where 풅 = (0, 0, 0)), the biases on
푃훼(2) and 푃훼(3) are not equal to −푃훼(1) and −푃훼(4) so there
is no net cancellation of biases in the calculation of SUCRA훼 .
The total bias on rank probabilities increases for more irreg-
ular networks (higher values of ℎ2∕푘̂2), and as a consequence
the bias on SUCRA also increases with the irregularity of the
graph.
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FIGURE 9 The effect of degree irregularity on a network’s
total rank probability bias. Data from networks with multi-arm
trials is shown as blue squares.
The data in Figures 6 to 8 indicate that reducing the net-
work’s irregularity improves the precision of treatment effect
estimates and reduces bias on ranking statistics in the case
of treatments with varying degrees of effectiveness. Our con-
clusions regarding the use of network heterogeneity for the
planning of future studies are therefore also valid in this more
realistic scenario.
3.4 Multi-arm trials
The results presented so far are for networks made up exclu-
sively of two-arm trials. However, approximately 85% of net-
work meta-analyses in the literature contain multi-arm trials45.
We therefore test if our findings generalise to networks includ-
ing multi-arm trials. We focus on complete-loop networks
(Figure 2(c)) as this allows us to introduce three-arm and four-
arm trials without changing the overall shape of the network (a
full loop remains a full loop if further trials are added to it). The
networks simulated in this section are designed specifically
to cover a wide range of degree irregularities. We note that
including more multi-arm trials in a network will, in general,
reduce its irregularity.
For a given value of the degree irregularity, ℎ2∕푘̂2, we gen-
erated synthetic trial data on complete-loop networks with
different combinations of two-arm, three-arm and four-arm tri-
als. We focus on the case of equally effective treatments, and
report the outcome at network-level. Treatment-specific out-
comes are provided in the Supplementary Material44 (Figures
S25 to S47). In all cases, the relationship between bias of rank
probability and the number of studies per treatment follows the
same pattern as in Figure 3.
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FIGURE 10 The effect of degree irregularity on a network’s
total standard deviation of treatment effect estimates. Data
from networks with multi-arm trials is shown as blue squares.
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FIGURE 11 The effect of degree irregularity on a network’s
total bias on SUCRA values. Data from networks with multi-
arm trials is shown as blue squares.
We show |Δ푃 |, SD and |ΔSUCRA| as a function of network
irregularity in Figures 9 to 11 respectively. The data from net-
works involving multi-arm trials is indicated by blue squares;
we include the data for networks of two-arm trials (red circles)
to allow comparison. As for the case of two-arm trials, the total
magnitude of the bias of rank probabilities and the total stan-
dard deviation of treatment effects increase with ℎ2∕푘̂2, while
the bias on SUCRA is largely unaffected by network irregular-
ity. When networks are sufficiently irregular, the presence of
multi-arm trials appears to reduce SD with respect to networks
consisting only of two-arm trials (Figure 10).
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FIGURE12 The effect of the total number of studies in a network on the accuracy of the estimate for the heterogeneity parameter
휏. Panel (a) is for networks made up exclusively of two-arm trials and compares networks with equally effective and non-equally
effective treatments. Panel (b) includes networks with 풅 = (0, 0, 0) only and networks with multi-arm trials are shown as blue
squares.
These results show that our findings concerning both within-
network and between-network comparisons can be generalised
to networks containing multi-arm trials.
3.5 Data-generating models
All data so far was produced using the data-generating model
‘Normal’ (see Sec. 2.7). We also carried out a similar anal-
ysis using data from the ‘Euclidean’ and ‘Uniform’ methods.
The only difference we observe is in the magnitude of the
standard deviation of treatment effects. While the relationship
between network irregularity, ℎ2∕푘̂2, and total standard devi-
ation, SD, was not affected by the choice of DGM, the values
of SD were lowest for the ‘Euclidean’ method and highest for
the ‘Uniform’ method. This is not surprising as the ‘Euclidean’
method restricts the range of absolute treatment effects that
can be sampled and thus reduces variation in the event rates.
The ‘Uniform’ method is the least restrictive in this sense. All
other results were consistent between the three DGMs (see
Figures S48 to S50 in the Supplementary Material44). This
demonstrates that the effects we observe are due to the network
geometry, and are not specific to any data-generating model.
3.6 Bias of the heterogeneity parameter, 휏
The data in Figure 12 shows that bias of the heterogeneity
parameter, 휏, decreases with the total number of studies in the
network. This is the case irrespective of whether the treatments
have uniform or varying effects (풅 = ퟎ or 풅 ≠ ퟎ), and for net-
works with two-arm and multi-arm trials. The bias of 휏 is not
affected by the network’s irregularity ℎ2∕푘̂2 (see Figure S51 in
the Supplementary Material44). Therefore adding any trial to
the network improves the accuracy of the estimate of 휏.
The true value of 휏 in Figure 12 is 0.1; we note that 휏 is con-
siderably overestimated in all cases we tested. To understand
this, it is useful to recall that 휏 characterises the variation of
the relative effects between any two treatments across trials in
the random-effects model. Additional randomness originates
from the sampling of event numbers in each trial arm. This is
the case both in real-world trial data and in simulation studies
(in the latter the sampling is from the binomial distributions
for the respective trial arms). Some of this sampling noise may
be attributed to between-trial variability by the NMA method,
leading to an overestimation of 휏.
4 SUMMARY AND DISCUSSION
4.1 Variation of treatment effect uncertainty
is associated with biased rank probabilities
We have carried out simulation studies of network meta-
analysis in random-effects models. These simulations reveal
that disparity in the number of studies different treatments are
involved in can lead to variation between the standard devi-
ations of effect estimates. This in turn appears to generate a
systematic bias in estimated rank probabilities. In line with
previous simulations of NMA for fixed-effects models24, the
probability of a treatment being ranked best is overestimated
for treatments included in the fewest number of studies, and
underestimated for treatments which are part of a large num-
ber of studies. In addition, our study of networks with four
treatments found the same trend for the probability of being
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FIGURE 13 Illustrative example of posterior distributions
of treatment effect estimates for four treatments in a network
meta-analysis. The posterior distributions have the same mean
value but varying standard deviation. Treatment 푇1 has the
most narrow distribution, followed by 푇2, 푇3 and 푇4 which has
the widest distribution.
ranked last. The probability of being ranked second and third
best is subject to a bias in the opposite direction. These trends
correspond to an increased standard deviation of treatment
effect estimates for treatments compared in a smaller number
of studies.
A general connection between standard deviation of effect
estimates and bias of rank probabilities has previously been
recognised in Rücker et al (2015)15. Our work establishes fur-
ther details of the mechanics leading to biased rank probabili-
ties. We illustrate this in Figure 13, where we show a fictitious
example of posterior distributions for the effectiveness of four
different treatments. The four distributions have equal mean
values, but varying standard deviations. The distribution of
treatment 푇4, which has the largest standard deviation, has
higher density than the other treatments at very large and very
small values of the treatment effect. This means that although
the most probable value of the effect of treatment 푇4 is the
same as for the other treatments, 푇4 is more likely than the
other treatments to have an effect that is the largest or the small-
est. Therefore treatment 푇4 has the highest probability of being
ranked best and the highest probability of being ranked worst.
Conversely, treatment 푇1 has the lowest standard deviation.
Therefore, it is less likely to have extreme values of treat-
ment effect and thus has a higher probability of being ranked
second or third. Rücker et al (2015)15 used a similar expla-
nation to demonstrate that the probability that one treatment
is better than another can be misleading when the posterior
distributions of their effects have considerable overlap.
This stylised example demonstrates that biased rank proba-
bilities can result if the uncertainty on some treatment effects
is larger than on others. This effect is also to be expected when
the distributions of treatment effects have different means, pro-
vided the differences in these means are small compared to
their standard deviations.
Our analysis shows that the posterior distributions of treat-
ment effect estimates are the most narrow for treatments
included in themost studies and widest for those that have been
studied the least. As a consequence, biases of rank probabili-
ties may arise if different treatments are involved in disparate
numbers of studies, i.e., for large irregularity of the network.
The simulations presented in this paper are an explicit
demonstration of biases that can occur in the comparison of
multiple treatments. We have also suggested how they might
originate from the structure of the network of treatments and
trials. Understanding the origins of bias, we think, is vital for
interpreting rank probabilities in network meta-analyses, and
contributes to our understanding of the NMA method and its
limitations.
4.2 Planning future studies to reduce the
irregularity of the network
Planning future clinical trials based on existing evidence from
network meta-analysis can reduce the resources and number
of participants required to obtain results of a given preci-
sion46,47,48. While the design of future trials based on pairwise
meta-analysis has received significant attention49,50,51, meth-
ods using the outcome of network meta-analysis are less devel-
oped. Current approaches in this area52,47 are computationally
intensive and become increasingly laborious as the network
becomesmore complex. Our results show that the degree irreg-
ularity of a network, ℎ2∕푘̂2, can provide guidance on the choice
of future trials without the need for extensive simulations. The
degree of a treatment in the graph is the number of trials it is
involved in, and the irregularity of a network describes how
this degree varies across treatments. This is easily obtained
from the network.
Irregularity is a better indicator of the quality of a net-
work meta-analysis than the total number of studies in the
network. As we have shown, networks with a more homoge-
neous distribution of studies between treatments have more
precise treatment effect estimates and smaller bias of rank
probabilities.
Degree irregularity is therefore a useful metric for work-
ing out which comparisons could be made in future studies to
improve the quality of an existing NMA. For example, con-
sider a network of four treatments with 푲 = (1, 0, 0, 19, 0, 1)
and ℎ2∕푘̂2 = 0.82 as shown on the left in Figure 14. Now imag-
ine resources are available to add ten new two-arm studies to
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FIGURE 14 Example of three different geometries that can
be created by adding a fixed number of studies to an existing
network.
this network. If (a) we add all ten studies to the most connected
comparison (푇2 − 푇3) then we obtain 푲 = (1, 0, 0, 29, 0, 1),
and the network’s irregularity increases to 0.88. We may be
more inclined to populate a comparison that currently has no
direct evidence such as 푇1 − 푇3 [(b) in Figure 14] or 푇1 − 푇4
[(c)]. The former leads to 푲 = (1, 10, 0, 19, 0, 1) and reduces
ℎ2∕푘̂2 to 0.48, while the latter has 푲 = (1, 0, 10, 19, 0, 1) and
reduces ℎ2∕푘̂2 to 0.08. These three possible ‘future’ networks
are shown on the right-hand side in Figure 14.
By simulating the original network and the three ‘future’
networks whilst keeping all other network characteristics con-
stant, we compare how adding the extra ten studies affects the
quality of the results. Table 2 summarises the total standard
deviation and total rank probability bias of these four networks.
TABLE 2 Degree heterogeneity and quality of NMA outcome
for the networks in Figure 14.
Network 푀 ℎ2∕푘̂2 SD |Δ푃 |
Original: 21 0.82 4.44 1.74
(a): 31 0.88 4.36 1.73
(b): 31 0.48 3.24 1.47
(c): 31 0.08 1.68 0.16
For network (a) the quality of the NMA is approximately
the same as for the original network whereas (b) and (c) show
a considerable reduction in SD and |Δ푃 |. The improvement
in both quantities for network (c) is markedly greater than in
network (b) even though in both cases the ten new studies were
added to a comparison with no existing direct evidence.
This example demonstrates that equality in the number of
studies per treatment is more important than equality in the
number of studies per comparison. Choosing future studies
that reduce degree irregularity may therefore help to improve
the precision of treatment effect estimates and the accuracy of
rank probabilities.
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